Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/58043
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ozdemir, Melek | - |
dc.contributor.author | Dogu, Gamze Gokoz | - |
dc.contributor.author | Taskoylu, Burcu Yapar | - |
dc.contributor.author | Demiray, Atike Gökçen | - |
dc.contributor.author | Çakan Demirel, Burçin | - |
dc.contributor.author | Doğan, Tolga | - |
dc.contributor.author | Güçlü Kantar, Taliha | - |
dc.contributor.author | Yaren, Arzu | - |
dc.contributor.author | Degirmencioglu, Serkan | - |
dc.contributor.author | Tas, Semra | - |
dc.contributor.author | Yildiz, Bedriye Acikgoz | - |
dc.contributor.author | Ozel, Gamze Serin | - |
dc.date.accessioned | 2024-10-20T16:20:47Z | - |
dc.date.available | 2024-10-20T16:20:47Z | - |
dc.date.issued | 2024 | - |
dc.identifier.issn | 2587-0262 | - |
dc.identifier.uri | https://doi.org/10.4274/nkmj.galenos.2024.93898 | - |
dc.identifier.uri | https://hdl.handle.net/11499/58043 | - |
dc.description.abstract | Aim According to the information obtained from the World Health Organization database, the incidence of hepatocellular carcinoma (HCC) in Turkey increased by 17.78% between the years of 2018 and 2020. In this study, we investigated the prognostic value of albumin-bilirubin (ALBI) score and lymphocyte-associated inflammation markers on overall survival (OS) and progression-free survival (PFS) in advanced hepatocellular carcinoma. Materials and Methods Data of 141 patients with advanced HCC were included in this study. ALBI score and lymphocyte-associated inflammatory marker were calculated. As a result, the prognostic significance of these tests for survival were evaluated. Results The median age was 65 years (min: 26-max: 88). There were 58 (41.1%) hepatitis B virus (HBV) positive, 20 (14.2%) hepatitis C (HCV) positive and 63 (44.7%) patients with no history of hepatitis. Cut-off values of ALBI score and lymphocyte-associated inflammation markers were found by receiver operating characteristic analysis. ALBI (p<0.001), aspartate aminotransferase-to-lymphocyte ratio (ALRI) (p<0.001), prognostic nutritional index (PNI) (p=0.030), hemoglobin, albumin, lymphocyte, and platelet score (HALP) (p=0.003) scores were significantly associated with survival. In multivariate analysis, being >= 65 years old [hazard ratios (HR): 2.13; 95% confidence interval (CI): 1.44-3.17; p<0.001], ALRI >= 30.79 (HR: 2.14; 95% CI: 1.20-3.82; p=0.009) predicted an increased risk of death and ALBI >=-2.54 (HR: 0.44, 95% CI: 0.29-0.69; p<0.001) predicted a decreased risk of death. Being >= 65 years old (HR: 174, 95% CI: 1.18-2.56; p=0.005) increased the risk of progression. Conclusion This study supports the statistically significant association of ALBI score and lymphocyte-associated inflammation markers (ALRI, PNI, HALP) with OS and PFS in advanced HCC patients. It is thought that this study will contribute to the literature and clinical practice. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Galenos Publ House | en_US |
dc.relation.ispartof | Namik Kemal Medical Journal | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | HCC | en_US |
dc.subject | ALBI score | en_US |
dc.subject | lymphocyte-associated inflammatory marker | en_US |
dc.subject | ALRI | en_US |
dc.subject | survival | en_US |
dc.subject | Cancer | en_US |
dc.subject | Cytokines | en_US |
dc.title | Prognostic value of albi score and lymphocyte-associated inflammation markers in advanced hepatocellular carcinoma: a single centre retrospective cross-sectional study | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 12 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.startpage | 155 | en_US |
dc.identifier.endpage | 162 | en_US |
dc.department | Pamukkale University | en_US |
dc.identifier.doi | 10.4274/nkmj.galenos.2024.93898 | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.wos | WOS:001325743200002 | en_US |
dc.institutionauthor | … | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.openairetype | Article | - |
item.cerifentitytype | Publications | - |
item.fulltext | With Fulltext | - |
item.grantfulltext | open | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
Appears in Collections: | Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
155-162.pdf | 1.4 MB | Adobe PDF | View/Open |
CORE Recommender
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.